651047-33-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(2,4,5-Trifluorophenyl)propanoic acid is utilized as a nonsteroidal anti-inflammatory drug (NSAID) for its analgesic, antipyretic, and anti-inflammatory capabilities. It is particularly effective in alleviating pain, reducing fever, and managing inflammation associated with various conditions such as arthritis, menstrual cramps, and other chronic pain syndromes.
Used in Pain Management:
In the field of pain management, 3-(2,4,5-Trifluorophenyl)propanoic acid serves as an analgesic, helping to mitigate discomfort and pain in patients suffering from different types of ailments, including but not limited to musculoskeletal disorders and post-operative pain.
Used in Fever Reduction:
3-(2,4,5-Trifluorophenyl)propanoic acid is employed as an antipyretic agent to lower elevated body temperatures caused by infections or other inflammatory processes, providing relief and supporting the body's natural cooling mechanisms.
Used in Inflammation Control:
For inflammation control, 3-(2,4,5-Trifluorophenyl)propanoic acid acts to decrease the signs and symptoms of inflammation, which can be beneficial in the treatment of conditions characterized by excessive or chronic inflammation, such as certain autoimmune diseases.
It is crucial to administer 3-(2,4,5-Trifluorophenyl)propanoic acid under the supervision of a healthcare professional to ensure safe usage and to minimize potential side effects or drug interactions.

Upstream product

• 888321-36-6 ethyl 3-(2,4,5-trifluorophenyl)acrylate 
• 165047-24-5 2,4,5-trifluorobenzaldehyde 
• 247170-17-8 3-(2,4,5-trifluoro-phenyl)-acrylic acid 

Downstream Products

• 130887-16-0 3-(2,4,5-Trifluorophenyl)-propan-1-ol 
• 1407666-56-1 (S)-4-benzyl-3-(3-(2,4,5-trifluorophenyl)propanoyl)oxazolidin-2-one 
• 1407666-69-6 C₁₅H₁₆F₃NO₃ 
• 1102373-43-2 C₉H₆ClF₃O 
• 1407666-61-8 (R)-t-butyl 4-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-4-oxo-3-(2,4,5-trifluorobenzyl)butanoate 
• 1407666-72-1 (R)-tert-butyl 3-(((benzyloxy)carbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoate 
• 1407666-67-4 (R)-4-(t-butoxy)-4-oxo-2-(2,4,5-trifluorobenzyl)butanoic acid 
• 1246960-25-7 (R)-3-(((benzyloxy)carbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoic acid 
• 1242069-63-1 (R)-benzyl (4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl)carbamate 
• 486460-32-6 sitagliptin 

Relevant academic research and scientific papers

Preparation method of sitagliptin

The invention discloses a preparation method of sitagliptin. The preparation method comprises the following steps: (1) carrying out a substitution reaction on a compound as shown in a formula I and bromoacetyl chloride to obtain a compound as shown in a formula II; (2) carrying out a cyclization reaction on the compound as shown in the formula III under conditions (i, ii and iii) to obtain a compound as shown in a formula IV; (3) removing HBr coupling from the compound as shown in the formula II and the compound as shown in the formula IV under the action of an alkali to obtain a compound as shown in a formula V; (4) reacting the compound as shown in the formula V with hydroxylamine to form a compound VI with a ketoxime structure; (5) carrying out a Beckmann rearrangement reaction on the compound as shown in the formula VI under the action of an acid to obtain a compound VII; and (6) hydrolyzing the compound as shown in the formula VII and carrying out decarboxylating under a strong heat condition to obtain the compound X, i.e., sitagliptin. The method for preparing sitagliptin has simple steps, uses easily-available raw materials, and is greatly reduced in side reactions and greatly increased in yield.

A concise enantioselective synthesis of (R)-selegiline, (S)-benzphetamine and formal synthesis of (R)-sitagliptin via electrophilic azidation of chiral imide enolates

A concise and high yielding enantioselective synthesis of (R)-selegiline, an anti-Parkinson's drug, (S)-benzphetamine, an anti-obesity agent, and (S)-sitagliptin, an anti-diabetic drug has been described starting from commercially available starting materials employing Evans' electrophilic azidation of chiral imide enolates as a key chiral inducing step, which proceeds in a highly diastereoselective manner (>99%).

NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS

Compounds of the general formula (I): (I)wherein m, n, R1, R2, R3 and R4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT2A receptor-related disorders or medical conditions.